Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

NOC-110

Other · developed by Nocion Therapeutics

Phase 2 Most advanced trial
1 Registered trials

What is NOC-110?

NOC-110 is an investigational drug studied in Refractory or Unexplained Chronic Cough.

At a glance

Also known as
taplucainium
Drug type
Other
Therapy area
Respiratory
Developer
Nocion Therapeutics
In trials of
IQV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06504446 Phase 2 Refractory or Unexplained Chronic Cough Active not recruiting IQV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Refractory or Unexplained Chronic Cough

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.